Inflammation-targeted cannabidiol-loaded nanomicelles for enhanced oral mucositis treatment

Drug Deliv. 2022 Dec;29(1):1272-1281. doi: 10.1080/10717544.2022.2027572.


One of the most common complications of cancer chemotherapy is oral mucositis (OM), a serious kind of oral ulceration, but its effective treatment remains a serious challenge. In this study, we used deoxycholic acid and fucoidan to prepare inflammation-targeting nanomicelles (FD), because fucoidan can target inflammation due to its high binding affinity for P-selectin. The hydrophobic anti-inflammatory drug cannabidiol (CBD) was then loaded into the hydrophobic core of FD. The resulting CBD-loaded FD micelles (CBD/FD) had uniform particle size and morphology, as well as favorable serum stability. Moreover, administration of the FD micelles via intravenous injection or in situ dripping in an OM mouse model enhanced the accumulation and retention of CBD. CBD/FD also showed a better anti-inflammatory effect compared to free CBD after local or systemic administration in vivo, while they accelerated OM healing and inhibited Ly6G inflammatory cell infiltration and NF-κB nuclear transcription. Our results show that CBD/FD nanomicelles are a promising agent for OM treatment.

Keywords: Oral mucositis; P-selectin; cannabidiol; inflammation; nanomedicine.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology
  • Anti-Inflammatory Agents / therapeutic use
  • Cannabidiol* / pharmacology
  • Inflammation / drug therapy
  • Mice
  • Micelles
  • Stomatitis* / chemically induced
  • Stomatitis* / drug therapy


  • Anti-Inflammatory Agents
  • Micelles
  • Cannabidiol

Grants and funding

This work was supported by the West China Hospital of Stomatology under Grant RD-03-202010; and College Students' Innovative Entrepreneurial Training Plan Program of Sichuan University under Grant 202110610233.